Advertisement

 

 

Rectal 1% tenofovir gel use associates with altered epidermal protein expression.

Author Information (click to view)

Romas L, Birse K, Mayer KH, Abou M, Westmacott G, Giguere R, Febo I, Cranston RD, Carballo-Diéguez A, McGowan I, Burgener A,


Romas L, Birse K, Mayer KH, Abou M, Westmacott G, Giguere R, Febo I, Cranston RD, Carballo-Diéguez A, McGowan I, Burgener A, (click to view)

Romas L, Birse K, Mayer KH, Abou M, Westmacott G, Giguere R, Febo I, Cranston RD, Carballo-Diéguez A, McGowan I, Burgener A,

Advertisement
Share on FacebookTweet about this on TwitterShare on LinkedIn

AIDS research and human retroviruses 2016 6 17()

Abstract

Rectal use of a 1% tenofovir (TFV) gel is currently being evaluated for HIV prevention. While careful assessment of mucosal safety of candidate microbicides is a primary concern, tools to assess mucosal toxicity are limited. Mass spectrometry-based proteomics is a sensitive and high throughput technique that can provide in-depth information on inflammation processes in biological systems. Here we utilized a proteomics approach to characterize mucosal responses in study participants involved in a phase 1 clinical trial of a rectal TFV-based gel. Project Gel was a phase 1 randomized (1:1), double-blind, multi-site, placebo-controlled trial in which 24 participants received rectal TFV or a universal placebo (HEC) over a course of 8 daily doses. Rectal mucosal swabs were collected after 0, 1 and 8 doses and were analyzed by label-free tandem mass spectrometry. Differential protein expression was evaluated using a combination of paired (time-effects), unpaired (across study arm) t-tests, and multivariate (LASSO) modelling. Within the TFV arm, 7% (17/249, p<0.05) and 10% (25/249, p<0.05) of total proteins changed after 1 and 8 daily applications of TFV gel, respectively, compared to 3% (7/249, p<0.05) and 6% (16/249, p<0.05) in the HEC arm. Biofunctional analysis associated TFV use with a decrease in epidermal barrier proteins (adj. p=1.21x10-10). Multivariate modelling identified 13 proteins that confidently separated TFV gel users (100% calibration and 96% cross-validation accuracy), including the epithelial integrity factors (FLMNB, CRNN, CALM), serpins (SPB13, SPB5) and cytoskeletal proteins (VILI, VIME, WRD1). This study suggested that daily rectal applications of a 1% TFV gel may be associated with mucosal proteome changes involving epidermal development. Further assessment of more extended use of TFV-gel usage is recommended to validate these initial associations.

Submit a Comment

Your email address will not be published. Required fields are marked *

sixteen + seven =

[ HIDE/SHOW ]